A Soy-peptide to Prevent Cancer
Lunasin may be introduced orally, topically or by intravenous injection of the pure synthetic peptide, the pure natural peptide or the synthetic or natural peptide in a food supplement.
Prophylatic or therapeutic biopharmaceutical to reduce the risk of various types of cancers such as prostate, breast and colon cancers Monitoring disease progression and efficacy of treatment in patients with neoplastic disease Screening other compounds with anti-neoplastic properties based on the gene expression profile
Lunasin, a peptide derived from soybean, has shown its anti-neoplastic properties (e.g., in cell transformation, foci formation, etc.) through its ability to control gene expression, but nothing is known about which specific genes fundamental to carcinogenesis are regulated by lunasin. Researchers at the University of California, Davis have identified specific target genes in malignant cells whose expression profile is altered in response to lunasin exposure. Gene expression profiling reveals that lunasin up-regulates genes that are involved in tumor suppression (anti-cell proliferation), cell death and cell division (e.g., mitotic checkpoint). Therefore, lunasin may be a transcription activator that up-regulates genes necessary for guarding or protecting cells from transformation events induced either by chemical carcinogens or oncogenes.
Patent Number: US7829277B2
Application Number: US2003591097A
Inventor: Rodriguez, Raymond | Magbanua, Mark Jesus Mendoza
Priority Date: 1 Mar 2004
Priority Number: US7829277B2
Application Date: 6 Aug 2007
Publication Date: 9 Nov 2010
IPC Current: C12Q000168 | C07H002102 | C07H002104
US Class: 43500616 | 435006 | 5360235 | 53602431
Assignee Applicant: The Regents of the University of California
Title: Methods for identifying compounds that suppress chemically-induced carcinogenesis
Usefulness: Methods for identifying compounds that suppress chemically-induced carcinogenesis
Summary: The method is useful for screening a test compound for anti-neoplastic activity, monitoring the efficacy of a prophylactic treatment of a subject having at least one risk factor for a neoplastic disease, and monitoring the efficacy of a treatment of a subject having a neoplastic disease. The methods and the compounds can be used for treating or preventing neoplastic growth in a mammal.
Novelty: Screening agent for anti-neoplastic activity comprises measuring expression levels of genes selected from those up-regulated in cells after exposure to lunasin before and after addition of the compound such as kinectin 1 and laminin, beta 1
Disease Diagnostic/Treatment
Cancer/Tumor
7829277
Related Technologies Additional Technologies by these Inventors Tech ID/UC Case 11441/2004-404-0 Related Cases 2004-404-0
USA
